Levothyroxine Tablets Recall for Wrong Strength Product Mix-Up
Alvogen is recalling one bottle of Levothyroxine Sodium 150mcg tablets (lot MHA21825) that was found to contain 88mcg tablets instead. The product was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving a thyroid medication with incorrect tablet strength, creating a dosing-error risk. No illnesses or injuries reported, but wrong dosage of an essential medication poses potential health consequences.
Plain-English summary
Alvogen, Inc. is recalling a bottle of Levothyroxine Sodium Tablets (Thyro-Tabs), 150mcg strength, from lot number MHA21825 (expiration date December 31, 2027). A pharmacy reported that one bottle from this lot contained 88mcg tablets instead of the labeled 150mcg tablets.
This is a product mix-up affecting a single bottle that was distributed nationwide. Consumers who have this product should check their bottle and contact their pharmacy if they have the affected lot number.
Patients taking this medication should not stop their treatment without consulting their healthcare provider. Anyone with the affected product should consult with their pharmacist or doctor about appropriate next steps.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Alvogen, Inc
- Category
- Drug — Thyroid Medication
- Hazard
- dosing-error
- product-mix-up
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # MHA21825
- Exp Date: December 31
- 2027
UPCs (11)
- 0347781649906
- 0347781671907
- 0347781643904
- 0347781657901
- 0347781640903
- 0347781651909
- 0347781662905
- 0347781665906
- 0347781646905
- 0347781654900
- 0347781659905
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Subpotent Content
FDA (Drugs) · 2026-04-01
- HighLevothyroxine Sodium Tablets Recalled for Subpotency Issue Nationwide
FDA (Drugs) · 2025-10-15
- ModerateLevothyroxine Sodium Tablets Recalled Due to Subpotent Drug Content
FDA (Drugs) · 2025-07-23
- HighLevothyroxine Sodium Tablets Recalled Due to Below-Specification Potency
FDA (Drugs) · 2025-07-23
- HighLevothyroxine Sodium 150 mcg Tablets Recalled for Subpotency
FDA (Drugs) · 2025-07-23
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27